RecruitingPhase 4NCT05932472

Randomized Comparison of Morning Versus Bedtime Administration of Aspirin: A Cardiovascular Circadian Chronotherapy (C3) Trial


Sponsor

Tor Biering-Sørensen

Enrollment

32,706 participants

Start Date

Jan 15, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

Wide variability in the antiplatelet effects of aspirin may lead to recurrent thromboembolic events. Several pilot studies have suggested potential benefits of taking aspirin at bedtime rather than in the morning. The primary objective of this study is to examine whether aspirin administration at bedtime versus in the morning provides a superior reduction in the incidence of major adverse cardiovascular events among patients with or without established atherosclerotic cardiovascular disease, who are already taking aspirin.


Eligibility

Min Age: 18 Years

Inclusion Criteria3

  • Age >=18 years
  • Current chronic treatment with aspirin (as recorded in the Danish National Prescription Registry and confirmed by the participant via questionnaire)
  • Signed informed consent

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGAspirin

Aspirin at currently prescribed dose


Locations(1)

Center for Translational Cardiology and Pragmatic Randomized Trials, Department of Cardiology, Copenhagen University Hospital - Herlev and Gentofte

Hellerup, Denmark

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT05932472


Related Trials